Despite the reduced expression of DAT on PBL plasma membrane in PD patients, intracellular concentrations of DA were significantly increased by L-DOPA therapy [80, 83], indicating the efficiency of DA re-uptake mechanisms. The gene discussed is SLC6A3; the disease is Parkinson disease.